OmniAb, Inc.
OABI
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRatā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.89
Price-0.53%
-$0.01
1Y
Price
Market Cap
$203.406m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-478.3%
EBITDA Margin-738.0%
Net Profit Margin-444.2%
Free Cash Flow Margin-478.3%
EBITDA Margin-738.0%
Net Profit Margin-444.2%
Free Cash Flow MarginRevenue
$21.094m
-20.1%
1y CAGR-28.3%
3y CAGR-3.7%
5y CAGREarnings
-$63.668m
-2.6%
1y CAGR-50.6%
3y CAGR-33.6%
5y CAGREPS
-$0.58
+4.9%
1y CAGR-36.9%
3y CAGR-29.8%
5y CAGRBook Value
$277.444m
$309.690m
Assets$32.246m
Liabilities$21.069m
DebtDebt to Assets
6.8%
-0.4x
Debt to EBITDAFree Cash Flow
-$35.255m
+15.1%
1y CAGR-1963.4%
3y CAGR-1500.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company